133 related articles for article (PubMed ID: 25065557)
21. Heparanase procoagulant effects and inhibition by heparins.
Nadir Y; Brenner B
Thromb Res; 2010 Apr; 125 Suppl 2():S72-6. PubMed ID: 20434010
[TBL] [Abstract][Full Text] [Related]
22. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
23. Tissue factor-heparanase complex: intracellular nonhemostatic effects.
Ghanem S; Keren-Politansky A; Kaplan V; Crispel Y; Nadir Y
Res Pract Thromb Haemost; 2023 Aug; 7(6):102179. PubMed ID: 37767062
[TBL] [Abstract][Full Text] [Related]
24. Clinical and prognostic significance of coagulation assays in lung cancer.
Tas F; Kilic L; Serilmez M; Keskin S; Sen F; Duranyildiz D
Respir Med; 2013 Mar; 107(3):451-7. PubMed ID: 23200643
[TBL] [Abstract][Full Text] [Related]
25. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy.
Chang CH; Hsiao CF; Yeh YM; Chang GC; Tsai YH; Chen YM; Huang MS; Chen HL; Li YJ; Yang PC; Chen CJ; Hsiung CA; Su WC
Int J Cancer; 2013 May; 132(9):1977-85. PubMed ID: 23034889
[TBL] [Abstract][Full Text] [Related]
26. Heparanase, tissue factor, and cancer.
Nadir Y; Vlodavsky I; Brenner B
Semin Thromb Hemost; 2008 Mar; 34(2):187-94. PubMed ID: 18645924
[TBL] [Abstract][Full Text] [Related]
27. Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin.
Gezelius E; Flou Kristensen A; Bendahl PO; Hisada Y; Risom Kristensen S; Ek L; Bergman B; Wallberg M; Falkmer U; Mackman N; Pedersen S; Belting M
PLoS One; 2018; 13(11):e0207387. PubMed ID: 30412630
[TBL] [Abstract][Full Text] [Related]
28. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis.
Goldin-Lang P; Tran QV; Fichtner I; Eisenreich A; Antoniak S; Schulze K; Coupland SE; Poller W; Schultheiss HP; Rauch U
Oncol Rep; 2008 Jul; 20(1):123-8. PubMed ID: 18575726
[TBL] [Abstract][Full Text] [Related]
29. Elevated platelet count is a strong predictor of poor prognosis in stage I non-small cell lung cancer patients.
Ji Y; Sheng L; Du X; Qiu G; Su D
Platelets; 2015; 26(2):138-42. PubMed ID: 24679181
[TBL] [Abstract][Full Text] [Related]
30. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
[TBL] [Abstract][Full Text] [Related]
31. Prognostic role of serum p53 antibodies in lung cancer.
Mattioni M; Soddu S; Prodosmo A; Visca P; Conti S; Alessandrini G; Facciolo F; Strigari L
BMC Cancer; 2015 Mar; 15():148. PubMed ID: 25884692
[TBL] [Abstract][Full Text] [Related]
32. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII.
Nadir Y; Brenner B; Fux L; Shafat I; Attias J; Vlodavsky I
Haematologica; 2010 Nov; 95(11):1927-34. PubMed ID: 20634491
[TBL] [Abstract][Full Text] [Related]
33. Increased human tumor necrosis factor-α levels induce procoagulant change in porcine endothelial cells in vitro.
Lee KG; Lee H; Ha JM; Lee YK; Kang HJ; Park CG; Kim SJ
Xenotransplantation; 2012; 19(3):186-95. PubMed ID: 22702470
[TBL] [Abstract][Full Text] [Related]
34. Heparanase and coagulation-new insights.
Nadir Y
Rambam Maimonides Med J; 2014 Oct; 5(4):e0031. PubMed ID: 25386347
[TBL] [Abstract][Full Text] [Related]
35. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
[TBL] [Abstract][Full Text] [Related]
36. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
[TBL] [Abstract][Full Text] [Related]
37. Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival.
Quiros RM; Rao G; Plate J; Harris JE; Brunn GJ; Platt JL; Gattuso P; Prinz RA; Xu X
Cancer; 2006 Feb; 106(3):532-40. PubMed ID: 16388520
[TBL] [Abstract][Full Text] [Related]
38. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells.
Nadir Y; Brenner B; Gingis-Velitski S; Levy-Adam F; Ilan N; Zcharia E; Nadir E; Vlodavsky I
Thromb Haemost; 2008 Jan; 99(1):133-41. PubMed ID: 18217145
[TBL] [Abstract][Full Text] [Related]
39. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer.
Graziano SL; Tatum AH; Gonchoroff NJ; Newman NB; Kohman LJ
Clin Cancer Res; 1997 Jan; 3(1):87-93. PubMed ID: 9815542
[TBL] [Abstract][Full Text] [Related]
40. Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors.
Voltolini L; Bongiolatti S; Luzzi L; Bargagli E; Fossi A; Ghiribelli C; Rottoli P; Gotti G
Eur J Cardiothorac Surg; 2013 Jan; 43(1):e17-23. PubMed ID: 23129356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
